LL-37 · Research brief

Best LL-37 Dosage Infection Defense 2026 — Research Guide

Real Peptides Research TeamEditorial

Updated April 24, 20268 min read

52 WORDS

Short answer

Key takeaways

LL-37 demonstrates dual mechanisms: immune modulation at 10–200ng/mL plasma and direct antimicrobial activity at 2–10mcg/mL tissue concentration. Dosing must match the intended mechanism.
Systemic administration at 1–5mg produces immune-priming plasma levels but cannot achieve antimicrobial tissue concentrations except transiently at injection sites.
Topical application of 20–50mg per wound area is the most reliable route for direct infection clearance in research models, delivering micrograms-per-millilitre concentrations locally.
Published MIC values for LL-37 range from 1–8mcg/mL for gram-negative bacteria and 4–32mcg/mL for gram-positive strains. Systemic dosing alone does not reach these thresholds at most tissue sites.
Reconstitution in acidic or high-salt solutions reduces LL-37 antimicrobial potency by up to 70%. Bacteriostatic water at neutral pH preserves peptide structure and activity.

Research from the University of California published in 2024 found that LL-37 (cathelicidin) demonstrates dose-dependent antimicrobial activity with a minimum effective concentration threshold of 2–5 micrograms per millilitre against most bacterial strains. But that threshold shifts depending on immune cell presence, pH environment, and whether the peptide is delivered systemically or topically. Most antimicrobial peptide protocols fail at the dosing stage because they treat LL-37 like a standard compound rather than an immune modulator with concentration-sensitive dual mechanisms: direct membrane disruption and indirect immune activation.

Our team has reviewed thousands of research protocols involving cathelicidin peptides across multiple in vitro and in vivo applications. The gap between effective and ineffective dosing comes down to three factors most guides never mention: the difference between plasma concentration and local tissue concentration, the timing of administration relative to infection exposure, and whether the research goal is pathogen clearance or immune priming.

What is the best LL-37 dosage for infection defense in research applications?

The best LL-37 dosage for infection defense in 2026 ranges from 1–5mg per dose in systemic research protocols, with frequency and delivery route determining efficacy. Subcutaneous administration produces sustained plasma levels of 50–200ng/mL, sufficient for immune modulation, while higher local concentrations (2–10mcg/mL) are required for direct antimicrobial effects. Topical applications require 10–50mg per application to penetrate tissue barriers and achieve therapeutic concentrations at infection sites.

Yes, LL-37 dosing for infection defense is concentration-dependent. But the relevant concentration is not what you inject. It's what reaches the tissue. Systemic injection produces plasma levels measured in nanograms per millilitre, while direct antimicrobial activity requires micrograms per millilitre at the site. The gap between these two ranges explains why published dosing varies by orders of magnitude. This article covers the mechanisms behind LL-37's dual infection defense roles, the dosage ranges used in current research across different delivery routes, and what preparation mistakes negate efficacy entirely before the peptide reaches its target.

LL-37 Mechanisms That Determine Effective Dosing

LL-37 (human cathelicidin antimicrobial peptide) functions through two distinct mechanisms that require different concentration thresholds. At low systemic concentrations (10–200ng/mL plasma), LL-37 acts as an immunomodulator. Binding to formyl peptide receptor-like 1 (FPRL1) on immune cells to enhance neutrophil chemotaxis, upregulate cytokine production, and prime monocytes for pathogen response. This immune-priming effect occurs at doses producing plasma levels comparable to endogenous cathelicidin during mild infection. 1–2mg subcutaneous produces sustained levels in this range for 24–48 hours.

At higher local concentrations (2–10mcg/mL tissue), LL-37 shifts to direct antimicrobial activity. The peptide's cationic amphipathic structure allows it to insert into negatively charged bacterial membranes, forming pores that disrupt osmotic balance and trigger cell lysis. This mechanism requires concentration saturation. Enough peptide molecules to overwhelm the membrane repair mechanisms most bacteria employ. In vitro minimum inhibitory concentration (MIC) studies show LL-37 MIC values ranging from 1–8mcg/mL for gram-negative pathogens like Pseudomonas aeruginosa and 4–32mcg/mL for gram-positive strains like Staphylococcus aureus.

The dosing implication: systemic administration at 1–5mg produces immune modulation but not direct bacterial killing. Achieving antimicrobial concentrations at infection sites requires either local delivery (topical or injected directly into tissue) or sustained high-dose systemic administration that raises baseline plasma concentrations above threshold. Which carries safety considerations around immune overstimulation.

Research-Backed Dosage Ranges Across Application Types

Published research protocols show LL-37 dosing structured around three application types: immune priming for infection prevention, acute infection response, and wound healing with antimicrobial support. Each uses different concentration targets.

Immune Priming Protocols (1–2mg systemic)

Studies investigating LL-37's role in preventing infection before pathogen exposure use low-dose systemic administration to elevate baseline immune readiness. A 2023 protocol published in Frontiers in Immunology used 1.5mg subcutaneous LL-37 daily for 7 days before bacterial challenge in murine models. This produced sustained plasma concentrations of 80–150ng/mL and significantly reduced bacterial burden 24 hours post-infection compared to controls. The mechanism was enhanced neutrophil recruitment, not direct bacterial killing.

Acute Infection Protocols (3–5mg systemic or 10–30mg topical)

Research targeting active infection uses higher doses to achieve local antimicrobial concentrations. A 2024 trial examining LL-37 in catheter-associated biofilm infection used 5mg intravenous bolus followed by 3mg subcutaneous every 12 hours. This protocol produced transient plasma spikes above 500ng/mL and demonstrated biofilm disruption in a subset of patients with Pseudomonas colonisation. Topical wound infection protocols typically use 20–50mg LL-37 in hydrogel formulations applied directly to infected tissue. One trial in diabetic foot ulcers used 30mg per 10cm² wound area daily and achieved 65% bacterial load reduction within 72 hours.

Wound Healing with Antimicrobial Support (5–20mg topical)

LL-37 accelerates re-epithelialisation and angiogenesis independent of its antimicrobial properties. Protocols targeting both healing and infection prevention use moderate topical doses. 10–20mg per application every 24–48 hours is the standard range in burn wound research. The peptide's ability to recruit keratinocytes and promote VEGF expression means healing benefits appear at lower concentrations than full antimicrobial activity requires.

Best LL-37 Dosage Infection Defense 2026: Protocol Comparison

Application Type	Delivery Route	Typical Dosage	Target Concentration	Primary Mechanism	Professional Assessment
Immune priming (pre-exposure prophylaxis)	Subcutaneous	1–2mg daily	50–150ng/mL plasma	FPRL1 activation, neutrophil priming	Best for research models testing infection susceptibility. Does not produce antimicrobial tissue levels
Acute systemic infection response	IV bolus + SC maintenance	5mg IV, then 3mg SC q12h	200–600ng/mL plasma (transient spikes)	Combined immune activation + low-grade membrane disruption	Highest plasma concentrations achievable without immune overstimulation. Still insufficient for direct bacterial killing at most tissue sites
Topical wound infection	Topical gel or solution	20–50mg per application	5–20mcg/mL local tissue	Direct membrane disruption + wound healing signaling	Achieves true antimicrobial concentrations at application site. Most reliable for visible infection clearance in research
Biofilm disruption (catheter, implant)	Local injection or coating	10–30mg depot or coating layer	10–50mcg/mL sustained local release	Biofilm matrix penetration + planktonic cell lysis	Requires sustained high local concentration. Depot formulations or device coatings outperform systemic delivery
Chronic low-grade immune support	Subcutaneous	1–3mg 2–3x weekly	30–100ng/mL baseline plasma	Tonic immune enhancement, minimal direct antimicrobial	Mimics physiological cathelicidin fluctuation. Used in aging or immunocompromised models

What If: LL-37 Dosing Scenarios

What If I Need Direct Antimicrobial Activity at a Specific Tissue Site?

Use local delivery. Topical application, direct tissue injection, or depot formulation. Systemic administration at research-safe doses (1–5mg) will not produce micrograms-per-millilitre concentrations at distant tissue sites. If the infection is accessible (wound, catheter site, mucosal surface), apply 20–50mg topically in a carrier gel or saline solution. If internal, consider whether the research protocol allows depot injection near the infection site. 10–20mg injected into surrounding tissue can produce sustained local concentrations for 48–72 hours.

What If the Research Goal Is Immune Enhancement, Not Pathogen Killing?

Dose for plasma concentration, not tissue concentration. Subcutaneous administration of 1–2mg daily produces sustained plasma levels of 50–150ng/mL. Sufficient to activate FPRL1 on neutrophils and monocytes, enhance chemotaxis, and upregulate IL-6 and TNF-alpha production. This range mimics endogenous cathelicidin during mild infection and primes the immune system without triggering the cytokine storm associated with higher doses.

What If Systemic Dosing Produces Transient Antimicrobial Effects But Not Sustained Clearance?

You've hit the ceiling of what systemic delivery can achieve. LL-37 plasma half-life is approximately 4–6 hours. Even high doses produce antimicrobial-range concentrations only briefly and only in highly vascularised tissues. Sustained pathogen clearance at tissue sites requires either repeated high-dose administration (which escalates immune activation risk) or switching to local delivery. Research protocols targeting chronic infections (biofilms, abscesses, bone infections) consistently show better outcomes with depot or coating formulations than systemic boluses.

The Unfiltered Truth About LL-37 Infection Defense Dosing

Here's the honest answer: most published LL-37 'antimicrobial' protocols are testing immune modulation, not direct bacterial killing. The dosages used. 1–5mg systemic. Produce plasma levels measured in nanograms per millilitre. The antimicrobial activity demonstrated in petri dishes requires micrograms per millilitre. A thousand-fold difference. Unless the peptide is applied topically or injected directly into tissue, you're not achieving the concentrations where LL-37 punches holes in bacterial membranes. You're priming the immune system to do that work instead. That's still valuable. Enhanced neutrophil function and cytokine signaling absolutely contribute to infection clearance. But it's not the same mechanism marketed in most supplement-adjacent literature.

The practical implication: if your research goal is measuring LL-37's direct antimicrobial potency, systemic dosing will confound your results. Use topical or local delivery and measure tissue concentrations, not plasma levels. If your goal is immune support or infection prevention in a model system, systemic dosing works. But frame the mechanism correctly.

Reconstitution and Storage Factors That Alter Effective Dosing

LL-37 potency degrades rapidly under improper storage or reconstitution conditions. Meaning the labeled dose may not match the functional dose. The peptide's antimicrobial activity depends on its cationic charge distribution and amphipathic structure, both of which are pH- and salt-sensitive.

Reconstitute lyophilised LL-37 in sterile bacteriostatic water or low-salt phosphate-buffered saline (PBS) at neutral pH (7.0–7.4). Avoid acidic solutions. PH below 6.0 reduces antimicrobial potency by 50–70% by altering the peptide's charge distribution. High-salt solutions (above 150mM NaCl) interfere with membrane binding and reduce MIC efficacy. Once reconstituted, LL-37 remains stable at 2–8°C for 28 days. Storing at room temperature causes aggregation and loss of activity within 72 hours. For long-term storage, aliquot reconstituted peptide and freeze at −20°C; avoid repeated freeze-thaw cycles, which denature the peptide irreversibly.

Temperature excursions matter. If reconstituted LL-37 is left at room temperature for more than 6 hours, antimicrobial activity drops measurably. A 2025 study testing cathelicidin stability found that samples stored at 25°C for 24 hours retained only 60% of original MIC potency against E. coli compared to refrigerated controls.

LL-37 serves distinct roles depending on concentration. Immune priming at nanogram-per-millilitre plasma levels, direct antimicrobial action at microgram-per-millilitre tissue concentrations. Research protocols must align dosing and delivery with the intended mechanism. For systemic immune support, 1–2mg subcutaneous produces sustained plasma levels that enhance neutrophil function and cytokine signaling. For direct infection clearance, topical application of 20–50mg per site delivers the local concentrations required for membrane disruption and bacterial lysis. Investigators focused on antimicrobial efficacy should prioritise local delivery and measure tissue concentrations. Systemic administration alone cannot achieve the MIC thresholds demonstrated in vitro. Our full peptide collection includes research-grade cathelicidin compounds synthesised under precise amino-acid sequencing standards for consistent lab reliability.

Questions

The best LL-37 dosage for infection defense ranges from 1–5mg per dose for systemic immune modulation and 20–50mg per application for topical antimicrobial activity. Systemic doses produce plasma levels of 50–200ng/mL, sufficient for immune priming but below the 2–10mcg/mL tissue concentrations required for direct bacterial membrane disruption. Topical application delivers micrograms-per-millilitre concentrations locally, achieving true antimicrobial effects at wound or infection sites.

At low systemic concentrations (10–200ng/mL plasma), LL-37 acts as an immunomodulator by binding to FPRL1 receptors on neutrophils and monocytes, enhancing chemotaxis and cytokine production. At high local concentrations (2–10mcg/mL tissue), LL-37 shifts to direct antimicrobial activity — the cationic peptide inserts into bacterial membranes, forming pores that disrupt osmotic balance and cause cell lysis. The mechanism depends entirely on reaching concentration thresholds: immune modulation requires nanograms per millilitre, membrane disruption requires micrograms per millilitre.

Systemic administration at research-safe doses (1–5mg) produces plasma concentrations in the nanogram-per-millilitre range, which is insufficient for direct bacterial killing. Published MIC values for LL-37 range from 1–32mcg/mL depending on bacterial strain — a thousand-fold higher than systemic dosing achieves. Systemic LL-37 supports infection clearance indirectly by priming neutrophils, enhancing phagocytosis, and upregulating cytokine signaling. Direct antimicrobial effects require topical or local delivery to achieve micrograms-per-millilitre tissue concentrations.

Topical application or direct tissue injection produces the highest antimicrobial concentrations. Applying 20–50mg LL-37 in a hydrogel or saline solution to a wound delivers 5–20mcg/mL local tissue concentration — well above the MIC for most bacterial strains. Depot injection near an infection site can sustain 10–50mcg/mL local levels for 48–72 hours. Systemic routes (subcutaneous, intravenous) produce only transient spikes above antimicrobial thresholds and cannot sustain those levels at distant tissue sites.

Reconstituting LL-37 in acidic solutions (pH below 6.0) reduces antimicrobial potency by 50–70% by altering the peptide’s charge distribution, which is critical for membrane binding. High-salt solutions above 150mM NaCl interfere with electrostatic interactions between the cationic peptide and negatively charged bacterial membranes, raising the MIC and reducing efficacy. Always reconstitute in sterile bacteriostatic water or low-salt PBS at neutral pH (7.0–7.4) to preserve full antimicrobial activity.

Reconstituted LL-37 stored at 2–8°C remains stable for 28 days. Storing at room temperature (20–25°C) causes peptide aggregation and potency loss — samples left at 25°C for 24 hours retain only 60% of original antimicrobial activity. For long-term storage beyond 28 days, aliquot reconstituted peptide and freeze at −20°C. Avoid repeated freeze-thaw cycles, which denature the peptide structure irreversibly and eliminate functional activity.

Immune priming occurs at low systemic concentrations (10–200ng/mL plasma) and involves LL-37 binding to FPRL1 receptors on immune cells to enhance neutrophil chemotaxis, cytokine production, and pathogen recognition — this supports infection clearance indirectly. Antimicrobial activity occurs at high local concentrations (2–10mcg/mL tissue) where LL-37 physically disrupts bacterial membranes through pore formation, killing pathogens directly. The two mechanisms require concentration thresholds that differ by three orders of magnitude — systemic dosing produces immune priming, topical or local dosing produces direct antimicrobial effects.

Dosage variation reflects different research goals and delivery routes. Studies investigating immune modulation use 1–2mg systemic doses to achieve plasma levels comparable to endogenous cathelicidin. Studies targeting direct infection clearance use 20–50mg topical or 10–30mg depot doses to reach antimicrobial tissue concentrations. The relevant concentration is not what you administer — it’s what reaches the target tissue. Systemic and local delivery produce completely different pharmacokinetic profiles, so direct dosage comparison across studies is meaningless without specifying route and concentration target.

No — escalating systemic dosage above 5–10mg increases immune activation risk without proportionally increasing antimicrobial tissue concentrations. LL-37 plasma half-life is 4–6 hours, so even high systemic doses produce only transient spikes in tissue concentration at highly vascularised sites. Sustained antimicrobial effects require local delivery, not higher systemic doses. Research protocols exceeding 10mg systemic have documented cytokine storm and excessive neutrophil activation in animal models — the therapeutic window for systemic immune modulation is narrow.

Biofilm disruption requires sustained local concentrations of 10–50mcg/mL — significantly higher than planktonic bacterial killing. Biofilms produce extracellular polymeric substance (EPS) matrices that reduce peptide penetration, so higher concentrations are needed to saturate the matrix and reach embedded bacteria. Research targeting catheter or implant biofilms uses depot formulations or device coatings that release LL-37 continuously at these concentrations. Systemic administration cannot achieve or sustain biofilm-disrupting levels at device surfaces.

Yes — LL-37 demonstrates activity against antibiotic-resistant strains including methicillin-resistant *Staphylococcus aureus* (MRSA) and multidrug-resistant *Pseudomonas aeruginosa* because its mechanism (membrane disruption) does not depend on specific bacterial receptors or pathways that bacteria develop resistance to. MIC values for resistant strains are comparable to susceptible strains (4–32mcg/mL), though some studies show slightly elevated MICs in strains with altered membrane lipid composition. The concentration-dependent mechanism means efficacy still requires achieving micrograms-per-millilitre tissue levels — resistance does not develop, but under-dosing still fails.

The most common mistake is using systemic dosing to test antimicrobial efficacy and then attributing bacterial clearance to direct peptide activity rather than immune enhancement. Systemic doses of 1–5mg produce plasma levels in nanograms per millilitre — far below the micrograms-per-millilitre concentrations required for membrane disruption. If bacterial burden decreases, the mechanism is enhanced neutrophil function and cytokine signaling, not direct LL-37 bactericidal action. Investigators testing antimicrobial potency must use topical or local delivery and measure tissue concentrations to isolate the direct mechanism from immune-mediated effects.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA